- Medicine (St Vincent's) - Research Publications
Medicine (St Vincent's) - Research Publications
Permanent URI for this collection
27 results
Filters
Reset filtersSettings
Statistics
Citations
Search Results
Now showing
1 - 10 of 27
-
ItemManagement of high risk chronic lymphocytic leukaemia (CLL) patients in AustraliaKuss, BJ ; Tam, CS (WILEY, 2017-12)BACKGROUND: Chronic lymphocytic leukaemia (CLL) frequently responds to chemoimmunotherapy combining cytotoxic chemotherapy and monoclonal antibodies. However, CLL is associated with significant genetic heterogeneity, and some high-risk forms are known to be chemo-resistant and associated with early relapse. AIMS: To review the current treatment paradigm of patients with high-risk disease, in particular those with del(17p) and TP53 variants. RESULTS: A 'watch and wait' approach is recommended for all patients who are asymptomatic. When symptomatic, fluorescence in situ hybridisation testing should be performed and gene sequencing considered subsequently to identify del(17p) and TP53 variants respectively. In the front-line setting, treatment within a clinical trial is the preferred option. In the relapsed or refractory setting, patients with del(17p) or TP53 aberrations should be offered treatment with a novel agent, such as ibrutinib, idelalisib-rituximab or venetoclax. However, of note, at the date of this publication venetoclax is not PBS reimbursed, and ibrutinib will not be reimbursed until 1 December 2017. CONCLUSION: Testing for del(17p) and TP53 variants identifies high-risk CLL that requires specialist management.
-
ItemThe absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximabJain, P ; Nogueras Gonzalez, GM ; Kanagal-Shamanna, R ; Rozovski, U ; Sarwari, N ; Tam, C ; Wierda, WG ; Thompson, PA ; Jain, N ; Luthra, R ; Quesada, A ; Sanchez-Petitto, G ; Ferrajoli, A ; Burger, J ; Kantarjian, H ; Cortes, J ; O'Brien, S ; Keating, MJ ; Estrov, Z (WILEY, 2018-01)The degree of somatic hypermutation, determined as percent deviation of immunoglobulin heavy chain gene variable region sequence from the germline (IGHV%), is an important prognostic factor in chronic lymphocytic leukaemia (CLL). Currently, a cut-off of 2% deviation or 98% sequence identity to germline in IGHV sequence is routinely used to dichotomize CLL patients into mutated and unmutated groups. Because dissimilar IGHV% cut-offs of 1-5% were identified in different studies, we wondered whether no cut-off should be applied and IGHV% treated as a continuous variable. We analysed the significance of IGHV% in 203 CLL patients enrolled on the original frontline fludarabine, cyclophosphamide and rituximab (FCR) trial with a median of 10 years follow-up. Using the Cox Proportional Hazard model, IGHV% was identified as a continuous variable that is significantly associated with progression-free (PFS) and overall survival (OS) (P < 0·001). Furthermore, we validated this finding in 323 patients treated with FCR off-protocol and in the total cohort (n = 535). Multivariate analysis revealed a continuous trend. Higher IGHV% levels were incrementally associated with favorable PFS and OS in both FCR-treated cohorts (P < 0·001, both cohorts). Taken together, our data suggest that IGHV% is a continuous variable in CLL patients treated with FCR.
-
ItemManagement of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucilTam, C ; Kuss, B ; Opat, S ; Boulos, J ; Marlton, P (WILEY, 2017-07)Patients with chronic lymphocytic leukaemia (CLL) are generally older, with many considered 'unfit' for fludarabine-cyclophosphamide-rituximab therapy. In these patients, the combination of obinutuzumab-chlorambucil may be an appropriate therapeutic choice. Obinutuzumab-chlorambucil has been demonstrated to improve overall survival rates compared to chlorambucil alone and to improve progression-free survival and overall response rates compared to rituximab-chlorambucil. This combination can lead to certain toxicities that need to be addressed through appropriate patient selection, pre-medication and management. In this paper, we discuss evidence-based and author-recommended practical management of first-line CLL patients receiving obinutuzumab-chlorambucil.
-
ItemFactors predicting the identification of new organisms in follow-up blood cultures drawn during episodes of neutropenic sepsisHeriot, GS ; Tam, C ; Waters, M-J (WILEY, 2018-08)
-
ItemTreatment of patients with Waldenstrom macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory GroupTalaulikar, D ; Tam, CS ; Joshua, D ; Ho, JP ; Szer, J ; Quach, H ; Spencer, A ; Harrison, S ; Mollee, P ; Roberts, AW ; Horvath, N ; Lee, C ; Zannettino, A ; Brown, R ; Augustson, B ; Jaksic, W ; Gibson, J ; Kalff, A ; Johnston, A ; Trotman, J ; Kalro, A ; Grigoriadis, G ; Ward, C ; Prince, HM (WILEY, 2017-01)Waldenström macroglobulinaemia (WM) is an indolent B-cell malignancy characterised by the presence of immunoglobulin M (IgM) paraprotein and bone marrow infiltration by clonal small B lymphocytes, plasmacytoid lymphocytes and plasma cells. The symptoms of WM are protean, often follow an asymptomatic phase and may include complications related to the paraneoplastic effects of IgM paraprotein. The revised 2016 World Health Organization classification includes the MYD88 L265P mutation, which is seen in >90% of cases, within the diagnostic criteria for WM. While treatment of WM has often been considered together with other indolent B cell lymphomas, there are unique aspects of WM management that require specific care. These include the unreliability of IgM and paraprotein measurements in monitoring patients prior to and after treatment, the lack of correlation between disease burden and symptoms and rituximab-induced IgM flare. Moreover, while bendamustine and rituximab has recently been approved for reimbursed frontline use in WM in Australia, other regimens, including ibrutinib- and bortezomib-based treatments, are not funded, requiring tailoring of treatment to the regional regulatory environment. The Medical and Scientific Advisory Group of the Myeloma Foundation Australia has therefore developed clinical practice guidelines with specific recommendations for the work-up and therapy of WM to assist Australian clinicians in the management of this disease.
-
ItemRecommendations for the diagnosis and initial evaluation of patients with Waldenstrom Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenstrom MacroglobulinaemiaCastillo, JJ ; Garcia-Sanz, R ; Hatjiharissi, E ; Kyle, RA ; Leleu, X ; McMaster, M ; Merlini, G ; Minnema, MC ; Morra, E ; Owen, RG ; Poulain, S ; Stone, MJ ; Tam, C ; Varettoni, M ; Dimopoulos, MA ; Treon, SP ; Kastritis, E (WILEY, 2016-10)The diagnosis of Waldenström macroglobulinaemia (WM) can be challenging given the variety of signs and symptoms patients can present. Furthermore, once the diagnosis of WM is established, the initial evaluation should be thorough as well as appropriately directed. During the 8th International Workshop for WM in London, United Kingdom, a multi-institutional task force was formed to develop consensus recommendations for the diagnosis and initial evaluation of patients with WM. In this document, we present the results of the deliberations that took place to address these issues. We provide recommendations for history-taking and physical examination, laboratory studies, bone marrow aspiration and biopsy analysis and imaging studies. We also provide guidance on the initial evaluation of special situations, such as anaemia, hyperviscosity, neuropathy, Bing-Neel syndrome and amyloidosis. We hope these recommendations serve as a practical guidance to clinicians taking care of patients with a suspected or an established diagnosis of WM.
-
ItemHigh-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphomaCheah, CY ; Joske, D ; Cull, G ; Gilbertson, M ; Opat, SS ; Tam, CS ; Wirth, A ; Seymour, JF (WILEY, 2017-09)
-
ItemPlasmablastic Richter transformation as a resistance mechanism for chronic lymphocytic leukaemia treated with BCR signalling inhibitorsChan, K-L ; Blombery, P ; Jones, K ; Lade, S ; Carney, D ; Tran, H ; Seymour, JF ; Tam, CS (WILEY, 2017-04)
-
ItemIbrutinib monotherapy as effective treatment of central nervous system involvement by chronic lymphocytic leukaemiaTam, CS ; Kimber, T ; Seymour, JF (WILEY, 2017-03)
-
ItemHigh prevalence of antibiotic allergies in cladribine-treated patients with hairy cell leukemia - lessons for immunopathogenesis and prescribingMeher-Homji, Z ; Tam, CS ; Siderov, J ; Seymour, JF ; Holmes, NE ; Chua, KYL ; Phillips, EJ ; Slavin, MA ; Trubiano, JA (TAYLOR & FRANCIS LTD, 2019-12-06)The relationship between hematological malignancy and chemotherapy on the prevalence of antibiotic allergy label (AAL) is ill-defined. We performed a multicenter retrospective case-control study comparing AAL rates among cladribine-treated hairy cell leukemia (C-HCL) cases, non-HCL cladribine-treated controls (control-1), and fludarabine-treated controls (control-2). The prevalence of AALs in C-HCL patients was 60%, compared with control-1 (14%, p < .01) and control-2 patients (25%, p < .01). The predominant phenotype was maculopapular exanthem (92%). The drugs implicated in AAL causality in C-HCL patients included beta-lactams (81%), trimethoprim-sulfamethoxazole (58%), and allopurinol (69%). C-HCL patients demonstrate high rates of AAL, potentially due to immune dysregulation, impacting beta-lactam utilization.
- «
- 1 (current)
- 2
- 3
- »